Back to results
US 2016/0252527 A1Published application
Assays for determining plasma kallikrein system biomarkers
AssigneeDyax Corp.
InventorsDaniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
Life of this patent
Estimating the term…
Abstract
Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
Claims41
An ex vivo activation method, comprising:
- incubating a plasma sample obtained from a subject with an activator of the plasma kallikrein (pKal) system;
- measuring the levels of intact high molecular weight kininogen (HMWK), cleaved HMWK, or both, in the plasma sample before and after the incubation;
- and
- determining the reduction of intact HMWK in the sample after the activation.
1 more element
A method for assessing plasma activation in a subject, comprising:
- providing a plasma sample from a subject;
- and
- measuring the level of cleaved HMWK in the plasma sample.
An ex vivo assay for determining plasma kallikrein (pKal) activity in a sample, comprising:
- incubating the sample with a pKal system activator in the presence of a pKal substrate, and
- measuring the activity of pKal based on the cleavage rate of the substrate.
Dependencies are inferred from the claim text.